Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

In a paper released in Addiction, scientists reported that people with a history of alcohol use disorder who were prescribed these medications were 50% less likely to binge drink. The results were ...

Does using Ozempic cause brain fog? It depends on who you ask. This article takes a closer look at what’s going on with ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

“GLP-1 drugs don’t just curb appetite – they dull the desire to drink at a metabolic level. With cravings suppressed and tolerance lowered. GLP-1 users report skipping drinks, stopping earlier or ...

Weight loss drugs like Ozempic have gained a lot of popularity However these medications are not without side effects One ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...